Table 1.
Demographic and clinical parameter distribution of the study population in April 2011 at the time of group assignment
| Parameter | Control Group (Protocol) | Treatment Group (SAM) | P |
|---|---|---|---|
| Age (mean ± SD) | 57±10 | 57±9 | 0.92 |
| Sex | 0.79 | ||
| Male | 22 | 20 | |
| Female | 9 | 11 | |
| Race | 0.99 | ||
| African American | 20 | 21 | |
| Caucasian | 11 | 10 | |
| Hemoglobin (g/dl) (mean ± SD) | 11.2±1.4 | 11.3±1.0 | 0.68 |
| ESA dosage (IU/wk) (median ± interquartile range) | 2000±6000 | 3000±5500 | 0.50 |
| Kt/V (mean ± SD) | 1.5±0.3 | 1.6±0.2 | 0.75 |
| Albumin (g/dl) (mean ± SD) | 4.0±0.4 | 4.0±0.3 | 0.91 |
| TSAT (%) (mean ± SD) | 29.5±8.7 | 32.7±11.7 | 0.23 |
| Ferritin (ng/ml) (median ± interquartile range) | 971±647.5 | 863±528.5 | 0.21 |
| Diabetes | 17 | 18 | 0.99 |
| CHF | 6 | 8 | 0.93 |
| Access | |||
| Fistula | 20 | 21 | 0.99 |
| Graft | 6 | 7 | 0.99 |
| Catheter | 5 | 3 | 0.73 |